secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2026-07-07T11:02:35+00:00
Accession:  0001104659-26-080930
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi Therapeutics' TTI-109 Phase 1 study confirms prodrug design, improved tolerability, and STAT3 target engagement
--------------------------------------------------------------------------------

- TTI-109 rapidly converted to TTI-101 within 2 hours, achieving equivalent plasma exposure at molar-equivalent doses.
- Diarrhea duration with TTI-109 was 0.46 days vs 3.35 days for TTI-101; similar to placebo.
- Pharmacodynamic data showed up to 60% reductions in STAT3-driven immune cell populations (Th17, Tfh, B cells).
- Company plans to advance TTI-109 into STAT3-driven dermatologic and GI diseases, subject to additional funding.
- No serious adverse events; one discontinuation due to transaminitis deemed unlikely related.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/0001104659-26-080930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/tm2619879d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer